They found that CXCL13+PD-1+ CD4+ T cells (equal to CD4.c16/17) augmented antitumor cytotoxicity through interaction with LAMP3+ DCs in tumor-draining lymph nodes (TDLNs). The gene discussed is CXCL13; the disease is neoplasm.